DIHYDROERGOTAMINE MESYLATE
Dihydroergotamine Mesylate Injection is a pharmaceutical agent indicated for the acute treatment of migraine headaches, including cases with or without aura. It is also approved for the acute treatment of cluster headache episodes. The medication is intended for the immediate management of these conditions rather than for preventative use.
How DIHYDROERGOTAMINE MESYLATE Works
Dihydroergotamine acts as an agonist at the 5-HT1B, 5-HT1D, and 5-HT1F receptors. Its efficacy in treating migraine is attributed to two primary mechanisms: 1) activation of 5-HT1B receptors located on intracranial blood vessels, leading to vasoconstriction, and 2) activation of 5-HT1D receptors on sensory nerve endings of the trigeminal system, which inhibits the release of pro-inflammatory neuropeptides (such as calcitonin gene-related peptide, or CGRP). It also interacts with alpha-adrenergic and dopaminergic receptors, which contributes to its complex pharmacological profile and potential side effects.
Details
- Status
- Discontinued
- First Approved
- 2003-04-28
- Routes
- NASAL, INJECTION
- Dosage Forms
- SPRAY, METERED, INJECTABLE
Companies
DIHYDROERGOTAMINE MESYLATE Approval History
What DIHYDROERGOTAMINE MESYLATE Treats
2 indicationsDIHYDROERGOTAMINE MESYLATE is approved for 2 conditions since its original approval in 2003. These indications span multiple therapeutic areas including oncology, immunology, and more.
- Migraine
- Cluster Headache
DIHYDROERGOTAMINE MESYLATE Boxed Warning
PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the co-administration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medicatio...
WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the co-administration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because CYP3A4 inhibition elevates the serum levels of dihydroergotamine, the risk for vasospasm leading to cerebral ischemia and/or ischemia of the extremities is increased. Hence, concomitant use of these medications is contraindicated. (See CONTRAINDICATIONS and WARNINGS )
DIHYDROERGOTAMINE MESYLATE Competitive Set
ProThree rings of competition based on shared molecular targets and treated indications.
Indication competitors
Same indication, different mechanism — what else might this patient receive?
Filters applied: drops same-active-ingredient (505(b)(2) reformulations), route-mismatch (topical vs systemic), and cross-therapeutic-area matches in same-indication rings.
Drugs Similar to DIHYDROERGOTAMINE MESYLATE
3 of 20FDA-approved drugs for similar conditions. Compare mechanisms and indications to understand treatment alternatives.
Active Pipeline
Ongoing clinical trials by development phase
Key Completed Trials
Completed studies with published results, ranked by significance
Trial Timeline
Full development history with FDA approval milestones
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
DIHYDROERGOTAMINE MESYLATE FDA Label Details
Indications & Usage
DIHYDROERGOTAMINE MESYLATE is indicated for the treatment of Migraine; Cluster Headache.
WARNING: PERIPHERAL ISCHEMIA FOLLOWING COADMINISTRATION WITH POTENT CYP3A4 INHIBITORS Serious and/or life-threatening peripheral ischemia has been associated with the co-administration of dihydroergotamine with potent CYP3A4 inhibitors including protease inhibitors and macrolide antibiotics. Because...
Looking for the branded version?
BREKIYA (AUTOINJECTOR)
Full clinical data, patents, trials, and competitive landscape for dihydroergotamine mesylate.
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.